Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise against tough blood cancer

NCT ID NCT02310321

Completed Disease control Sponsor: Astellas Pharma Inc Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 23 times

Summary

This study tested a new drug, gilteritinib, given together with standard chemotherapy for adults who were just diagnosed with acute myeloid leukemia (AML), a fast-growing blood cancer. The first part of the study looked for the safest dose of gilteritinib, and the second part checked how well the combination worked at getting patients into complete remission. A total of 97 people took part, and the focus was on those whose cancer had a specific genetic change (FLT3 mutation).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • SIte JP81011

    Ōmura, Nagasaki, Japan

  • Site JP00001

    Fukuoka, Japan

  • Site JP00002

    Maebashi, Gunma, Japan

  • Site JP00003

    Nagoya, Aichi-ken, Japan

  • Site JP00005

    Shinagawa-ku, Tokyo, Japan

  • Site JP00006

    Yokohama, Kanagawa, Japan

  • Site JP00007

    Kobe, Hyōgo, Japan

  • Site JP81001

    Maebashi, Gunma, Japan

  • Site JP81003

    Nagoya, Aichi-ken, Japan

  • Site JP81004

    Fukuoka, Japan

  • Site JP81005

    Yokohama, Kanagawa, Japan

  • Site JP81006

    Kobe, Hyōgo, Japan

  • Site JP81007

    Yoshida-gun, Fukui, Japan

  • Site JP81008

    Chiba, Japan

  • Site JP81009

    Okayama, Japan

  • Site JP81010

    Narita, Chiba, Japan

  • Site JP81012

    Nagasaki, Japan

  • Site JP81013

    Isehara, Kanagawa, Japan

  • Site JP81014

    Sapporo, Hokkaido, Japan

  • Site JP81015

    Sapporo, Hokkaido, Japan

  • Site JP81016

    Kyoto, Japan

  • Site JP81018

    Ōtake, Hiroshima, Japan

  • Site JP81019

    Osaka, Japan

  • Site JP81020

    Kanazawa, Ishikawa-ken, Japan

  • Site JP81021

    Osaka, Japan

  • Site JP81022

    Shimono, Tochigi, Japan

  • Site JP81023

    Tsukuba, Ibaraki, Japan

  • Site JP81024

    Yokohama, Kanagawa, Japan

  • Site JP81025

    Fukuoka, Japan

  • Site JP81026

    Fukuyama, Hiroshima, Japan

  • Site JP81027

    Nagoya, Aichi-ken, Japan

  • Site JP81028

    Kumamoto, Japan

  • Site JP81029

    Akita, Japan

  • Site JP81030

    Gifu, Japan

  • Site JP81031

    Fukushima, Japan

  • Site JP81032

    Shinagawa-ku, Tokyo, Japan

  • Site JP81033

    Kochi, Japan

  • Site JP81035

    Sendai, Miyagi, Japan

  • Site JP81036

    Mito, Ibaraki, Japan

  • Site JP81037

    Anjo, Aichi-ken, Japan

  • Site JP81038

    Toyohashi, Aichi-ken, Japan

  • Site JP81039

    Matsuyama, Ehime, Japan

  • Site JP81040

    Bunkyo-ku, Tokyo, Japan

  • Site JP81041

    Tenri, Nara, Japan

  • Site JP81043

    Himeji, Hyōgo, Japan

  • Site KR82001

    Seoul, South Korea

  • Site KR82002

    Incheon, South Korea

  • Site KR82003

    Seoul, South Korea

  • Site KR82004

    Seoul, South Korea

  • Site KR82005

    Busan, South Korea

  • Site KR82006

    Seoul, South Korea

  • Site TW88601

    Tainan, Taiwan

  • Site TW88602

    Taichung, Taiwan

  • Site TW88603

    Taoyuan, Taiwan

  • Site TW88604

    Kaohsiung City, Taiwan

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA FLT3-MUTATED ACUTE MYELOID LEUKEMIA